Copyright
©The Author(s) 2018.
World J Diabetes. Sep 15, 2018; 9(9): 141-148
Published online Sep 15, 2018. doi: 10.4239/wjd.v9.i9.141
Published online Sep 15, 2018. doi: 10.4239/wjd.v9.i9.141
Antidiabetic drug | Effect on epicardial adipose tissue |
Biguanides | No effect/Possible synergistic effect with DPP-4 and/or GLP-1[39,40] |
Alpha-Glucosidase Inhibitors | Lack of data concerning the effect of this class |
Thiazolidinediones | Decreased inflammatory cytokine release and thickness of EAT (pioglitazone) modulation of cellular hormonal profile (rosiglitazone)[49,50] |
Dipeptidyl peptidase-4 inhibitors | Reduction of EAT thickness (sitagliptin)[39] |
Glucagon-like peptide-1 receptor agonists | Reduction of EAT thickness (liraglutide and exenatide)[40,60] |
Sodium-glucose cotransporter 2 inhibitors | Reduction of EAT thickness (luseogliflozin, ipragliflozin, canagliflozin, dapagliflozin) and inflammation (luseogliflozin, ipragliflozin, dapagliflozin)[63-67] |
- Citation: Xourgia E, Papazafiropoulou A, Melidonis A. Effects of antidiabetic drugs on epicardial fat. World J Diabetes 2018; 9(9): 141-148
- URL: https://www.wjgnet.com/1948-9358/full/v9/i9/141.htm
- DOI: https://dx.doi.org/10.4239/wjd.v9.i9.141